Drugs / J591 177LU

Trials 4 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT00967577 Jul 2009 → Jun 2018 breast cancer, colorectal cancer, esophageal cancer, glioma +5 Weill Medical College of Cornell University Completed No outcome recorded
Phase 1 NCT00916123 May 2009 → Dec 2015 prostate cancer Weill Medical College of Cornell University Completed No outcome recorded
Phase 1 NCT00538668 Aug 2007 → Oct 2015 prostate cancer Weill Medical College of Cornell University Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00859781 Jun 2009 → Feb 2022 overdue prostate cancer Weill Medical College of Cornell University Active not recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03545165 Background Apr 2018 → Jul 2020 prostate cancer Weill Medical College of Cornell University Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as J591 177LU ChEMBL registry synonym — accepted as the source's own label CHEMBL2109559
Known as 177Lu-J591 “Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody” NCT00538668
4

NCT00967577

NCT00916123

NCT00859781

NCT03545165

Known as HUJ591-GS ChEMBL registry synonym — accepted as the source's own label CHEMBL2109559
Action Deplete “deliver a lethal dose of radiation to the areas of cancer” NCT00916123
Modality Monoclonal antibody “Following the administration of 177Lu-J591 mAb on day 0” NCT00538668
Route Intravenous “177Lu-J591 \[1.35 GBq/m2 or 36.5 mCi/m2\] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration” NCT03545165
Target FOLH1 “Glutamate carboxypeptidase II binding agent” CHEMBL2109559